|
Worldwide Liver disease Articles
Worldwide Liver disease News : Leptospirosis Tue, 07 Sep 2010 14:51:00 GMT Reportlinker.com announces that a new market research report is available in its catalogue:Worldwide Liver disease News : Data From Mipomersen Phase 3 Trial In heFH Patients Presented At ESC Tue, 07 Sep 2010 05:52:22 GMT Genzyme Corp. and Isis Pharmaceuticals Inc. announced that data from the phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH) were presented today at the European Society of Cardiology's Congress 2010 in Stockholm, Sweden.Phase 3 study of mipomersen in heFH patients meets primary endpoint with 28% LDL-C reduction Tue, 07 Sep 2010 06:42:31 GMT Genzyme Corp. and Isis Pharmaceuticals Inc. announced that data from the phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH) were presented at the European Society of Cardiology’s Congress 2010 in Stockholm, Sweden.Successful Completion Of First Clinical Trials On Potent New Hepatitis C Drug Mon, 06 Sep 2010 11:29:22 GMT The first clinical trials on a new investigational drug being developed to treat infections caused by Hepatitis C virus have been successfully completed. Completion of the initial phase (phase 1a) of trials of INX-189, discovered and first prepared by researchers at Cardiff University's Welsh School of Pharmacy in 2008, means the chances of it becoming an approved medicine have significantly ...Researchers complete INX-189 clinical trials for Hepatitis C virus Sat, 04 Sep 2010 04:12:12 GMT The first clinical trials on a new investigational drug being developed to treat infections caused by Hepatitis C virus have been successfully completed.SCH to honour organ donors Fri, 03 Sep 2010 06:15:09 GMT 03 September 2010 DOHA: Haroon Sultan from Bahrain is a living liver donor, who is now leading a normal life after donating part of his liver to his mother who had been suffering from Hepatitis C.BioWatch: Emergent wins more federal backing for anthrax vaccine Fri, 03 Sep 2010 08:53:51 GMT Emergent BioSolutions has won up to $28.7 million from the National Institute of Allergy and Infectious Diseases to help develop its next-generation anthrax vaccine candidate.Pfizer Picking Up FoldRx in Latest Rare Disease Buyout Thu, 02 Sep 2010 01:30:12 GMT Just days after Sanofi-Aventis SA's official bid for Genzyme Corp., big pharma's pursuit of orphan drugs continued with Pfizer Inc.'s plan to buy out privately held FoldRx Pharmaceuticals Inc. for rights to a drug for rare neurodegenerative disease transthyretin amyloid polyneuropathy (ATTR-PN).LSUHSC pediatric weight expert provides obesity trinity answers Thu, 02 Sep 2010 19:01:59 GMT ( Louisiana State University Health Sciences Center ) In a first person paper published in the Aug. 27, 2010 issue of Childhood Obesity, Dr. Melinda Sothern, director of health promotion and professor of public health at LSU Health Sciences Center New Orleans, provides three ways to deprogram the 1950s obesity trinity underlying the current obesity epidemic in the United States and protect ...Mayo urges tests for more than 3,000 in hepatitis fallout Thu, 02 Sep 2010 22:38:51 GMT Mayo Clinic’s world-renowned reputation is serving as both an asset and obstacle in efforts to determine the reach of a hepatitis increase tied to a former employee at its Jacksonville location. Mayo administrators invoked the medical provider’s lofty reputation often during news conferences, particularly when they sought to distance the organization from the worker’s actions. But that eminence ...Novartis Drug Tasigna® Approved In Switzerland After Fast-track Review For Treatment Of Patients With Newly Diagnosed ... Thu, 02 Sep 2010 13:41:51 GMT The Swiss health authority Swissmedic has granted approval for Tasigna® (nilotinib) 300 mg twice daily for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. Tasigna is the first new therapeutic option for newly diagnosed patients since the introduction of Glivec® (imatinib), providing a major advance for ...Roche Provides Update On FDA Application For T-DM1 Thu, 02 Sep 2010 13:41:41 GMT Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) issued a Refuse to File letter for accelerated approval for the company's trastuzumab-DM1 (T-DM1) Biologics License Application (BLA). As planned Roche will continue with its ongoing Phase III EMILIA registration study. Roche will continue to work with the FDA and expects a global regulatory submission ...Pfizer to acquire Massachusetts research firm Thu, 02 Sep 2010 06:13:12 GMT Pfizer Inc. announced Wednesday it plans to acquire a Massachusetts research company known for pioneering work on neurogenerative disorders, initially including Huntington's and Parkinson's diseasesPfizer to acquire FoldRx Pharmaceuticals Thu, 02 Sep 2010 06:42:30 GMT Pfizer Inc. and FoldRx Pharmaceuticals, Inc., a privately held drug discovery and clinical development company, announced that they have entered into an agreement under which Pfizer will acquire FoldRx.Pfizer to Acquire FoldRx Pharmaceuticals Wed, 01 Sep 2010 13:21:42 GMT FoldRx Focused on First-in-Class, Disease-Modifying, Oral Therapeutics to Treat Diseases Caused by P...GI Dynamics, Elemental Healthcare sign agreement for distribution of EndoBarrier Gastrointestinal Liner Thu, 02 Sep 2010 09:42:42 GMT GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced it has entered into a new agreement with Elemental Healthcare, based in Hungerford, Berkshire, for the distribution of the EndoBarrier Gastrointestinal Liner in England, Wales, Scotland, Northern Ireland and Ireland.Pfizer to Acquire FoldRx Pharmaceuticals Wed, 01 Sep 2010 16:13:53 GMT NEW YORK and CAMBRIDGE, Mass., Sept. 1 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) and FoldRx Pharmaceuticals, Inc., a privately held drug discovery and clinical development company, today announced that they have entered into an agreement under which Pfizer will acquire FoldRx. (Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO ) (Logo: [[[SHIFTOUT ...Data From Mipomersen Phase 3 Trial In heFH Patients Presented At ESC Wed, 01 Sep 2010 16:12:01 GMT Genzyme Corp. (NASDAQ: GENZ) and Isis Pharmaceuticals Inc. (NASDAQ: ISIS) announced that data from the phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH) were presented at the European Society of Cardiology's Congress 2010 in Stockholm, Sweden. The study met its primary endpoint with a 28 percent reduction in LDL-cholesterol, compared with an increase ...DR. OZ UNDERGOES A LIFE-SAVING COLONOSCOPY AND RECEIVES A SURPRISING DIAGNOSIS AS 'THE DR. OZ SHOW' LAUNCHES ITS ... Wed, 01 Sep 2010 16:47:58 GMT Additional shows airing during premiere week feature three major themes which will recur throughout the year - "5 to Know," "Just 10 Pounds" and "The Pulse."Pfizer to Acquire FoldRx Pharmaceuticals Wed, 01 Sep 2010 12:30:00 GMT Pfizer Inc. and FoldRx Pharmaceuticals, Inc., a privately held drug discovery and clinical development company, today announced that they have entered into an agreement under which Pfizer will acquire FoldRx. ÂDr. Oz Undergoes a Life-Saving Colonoscopy and Receives a Surprising Diagnosis as 'The Dr. Oz Show' Launches Its ... Wed, 01 Sep 2010 15:56:00 GMT Dr. Oz finds himself in the unfamiliar role of Patient when "The Dr. Oz Show" returns for its second season on Tuesday, September 7. Â As part of the second season premiere, the Emmy Award-winning host, who turned 50 in June, undergoes a colonoscopy to emphasize the critical role they can play in detecting and preventing colon cancer.Data from Mipomersen Phase 3 Trial in heFH Patients Presented at ESC Wed, 01 Sep 2010 07:14:23 GMT CAMBRIDGE, Mass. & CARLSBAD, Calif.--(BUSINESS WIRE)--Genzyme and Isis announced that data from the phase 3 study of mipomersen in patients with heFH were presented today at the European Society of Cardiology’s Congress 2010 in Stockholm, Sweden. |
Infectious and parasitic diseases |
|
|
< Home > |
||